inversores

SPINEART NEW LEADERSHIP ANNOUNCEMENT

Effective January 1st, 2022, Jerome Trividic has been named Chief Executive Officer of the Spineart Group.Jerome joined Spineart in 2011 and has since worked side by side with the company’s founders as Group Chief Strategy Officer and President of Spineart US. Prior to joining Spineart, Jerome was an investment banker with Lazard specialized in the healthcare industry. “Innovation, focused strategy and our employees around the world, are integral to ensuring our continued success as a key player in the global spine market. I’m honored to be at the helm of this talented group, leading Spineart into the next phase of our growth.” said Jerome Trividic. The executive leadership team working with Jerome is composed of Franck Pennesi, Chief Technical Officer; Guillaume Amblard, Chief Product Officer; Alessia Erlingher, named Chief Commercial Officer starting January 1st; Stephan Cori, Executive Vice President of Finance; and Yohan Stalder, Executive Vice President of Operations.Jérôme Levieux and Stéphane Mugnier-Jacob, co-founders and previously co-CEOs of Spineart, will continue to actively support the team as Board members and exclusive senior advisors.More information about Spineart’s Executive Committee and Board of Directors can be found here.

100TH U.S. PATIENT TREATED IN IDE CLINICAL TRIALS OF BAGUERA® C CERVICAL DISC PROSTHESIS

LAGUNA HILLS, CA, November 16, 2021 – Spineart USA Inc. announced today that the 100th surgery has been performed in their combined single-level and two-level U.S. Investigational Device Exemption (IDE) Clinical Trials of the BAGUERA® C Cervical Disc Prosthesis. Dr. Armen Khachatryan at The Disc Replacement Center, in Salt Lake City, UT, is currently the leading enroller for the single-level trial, and Dr. Hyun Bae at the Foundation for Spinal Restoration in Santa Monica, CA, is the leading enroller for the two-level trial. The BAGUERA® C implant is an investigational device designed to reconstruct the cervical disc following discectomy for symptomatic cervical disc disease. Descargar las noticias de prensa Descargar las noticias de prensa

SPINEART SA TODAY ANNOUNCED A PLANNED MANAGEMENT REORGANIZATION

In order to accelerate Spineart's international growth, Jérôme Levieux and Stéphane Mugnier-Jacob, Spineart’s founders and current co-CEOs, have decided to reorganize the company’s leadership team enabling them to focus on highly strategic activities.Effective January 1, 2022, Jérôme Trividic, currently group Chief Strategy Officer and President US, will be named group CEO. Jérôme Levieux and Stéphane Mugnier-Jacob will continue to support actively the team as exclusive senior advisors and Board members. Descargar las noticias de prensa Descargar las noticias de prensa

SPINEART ANNOUNCES EXECUTIVE APPOINTMENT

Olivier Balouka joins Spineart as Chief Administrative Officer. Spineart is pleased to announce the arrival of Olivier Balouka as Chief Administrative Officer, effective June 1st, 2021. He leads the Finance, Human Resources, Legal and IT departments. Descargar las noticias de prensa Descargar las noticias de prensa

FIRST U.S. PATIENT TREATED IN SINGLE-LEVEL IDE CLINICAL TRIAL OF BAGUERA® C CERVICAL DISC PROSTHESIS

LAGUNA HILLS, CA, March 2nd, 2021 – Spineart USA Inc. announced today that investigator, Dr. Byron Branch, at Carolina Neurosurgery and Spine Associates in Charlotte NC, performed the first surgery in the single-level U.S. Investigational Device Exemption (IDE) Clinical Trial of the BAGUERA® C Cervical Disc Prosthesis. The BAGUERA® C implant is an investigational device designed to reconstruct the cervical disc following single-level discectomy for symptomatic cervical disc disease. Descargar las noticias de prensa Descargar las noticias de prensa

FIRST U.S. PATIENT TREATED IN TWO-LEVEL IDE CLINICAL TRIAL OF BAGUERA® C CERVICAL DISC PROSTHESIS

LAGUNA HILLS, CA, February 26, 2021 – Spineart USA Inc. announced today that clinical principal investigator, Dr. Domagoj Coric at Carolina Neurosurgery and Spine Associates and Spine Division Chief at Atrium Musculoskeletal Institute in Charlotte NC, performed the first surgery in the two-level U.S. Investigational Device Exemption (IDE) Clinical Trial of the BAGUERA® C Cervical Disc Prosthesis. The BAGUERA® C implant is an investigational device designed to reconstruct the cervical disc following two-level discectomy at adjacent segments for symptomatic cervical disc disease. Descargar las noticias de prensa Descargar las noticias de prensa